Our CEO, Andrew Satz, recently spoke at Columbia University School of General Studies’ “Alumni in Conversation.” The subject of his talk was artificial intelligence. One of the questions posed to Andrew was what we were doing outside of coronavirus, along with the long term plans of our company.
Andrew explained that in addition to coronavirus, we’re also working on oncology and autoimmune diseases. Andrew also explained how we’re not simply looking to be an AI service company, but a 21st century pharmaceutical company. Give it a listen below.